Mitochondrial
NAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell and one of the most extensively studied molecules in longevity and cellular biology research. It serves two critical functions. First, it acts as an electron carrier in the mitochondria, converting nutrients into ATP, the primary fuel source for cellular activity. Second, it activates sirtuins, a family of proteins that regulate DNA repair, inflammation response, and metabolic signalling. Without sufficient NAD+, both processes slow significantly. Levels decline by up to 50% with age across multiple tissue types. This decline is directly linked to reduced mitochondrial efficiency, slower DNA repair, and increased markers of cellular senescence. Restoring NAD+ levels has been shown in preclinical and clinical models to partially reverse these effects at a cellular level. A January 2026 head-to-head trial published in Nature Metabolism confirmed that NMN and NR precursors approximately doubled circulating NAD+ levels within 14 days, with NMN and NR performing comparably at equivalent doses. The 500mg pen is the standard format for NAD+ research protocols. The 1000mg pen is the highest concentration available, designed for extended cycles or higher-dose applications.
€299.90 · 1000mg
Available options
Product information
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell and one of the most extensively studied molecules in longevity and cellular biology research. It serves two critical functions. First, it acts as an electron carrier in the mitochondria, converting nutrients into ATP, the primary fuel source for cellular activity. Second, it activates sirtuins, a family of proteins that regulate DNA repair, inflammation response, and metabolic signalling. Without sufficient NAD+, both processes slow significantly. Levels decline by up to 50% with age across multiple tissue types. This decline is directly linked to reduced mitochondrial efficiency, slower DNA repair, and increased markers of cellular senescence. Restoring NAD+ levels has been shown in preclinical and clinical models to partially reverse these effects at a cellular level. A January 2026 head-to-head trial published in Nature Metabolism confirmed that NMN and NR precursors approximately doubled circulating NAD+ levels within 14 days, with NMN and NR performing comparably at equivalent doses. The 500mg pen is the standard format for NAD+ research protocols. The 1000mg pen is the highest concentration available, designed for extended cycles or higher-dose applications.